11:10 AM EST, 01/28/2025 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) said Tuesday that it started a phase 3 registrational study to evaluate the efficacy, safety, and tolerability of osavampator as an adjunctive treatment to antidepressants for major depressive disorder.

The company said the study will enroll adults primarily diagnosed with major depressive disorder and have "inadequate response" to existing antidepressant treatment.

According to Neurocrine, a phase 2 study on osavampator met all primary and secondary endpoints and showed the investigational drug to be generally well-tolerated.

Price: 150.76, Change: +2.57, Percent Change: +1.73